2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Sales - EUR | 90.022 | 159.142 | 148.402 | 48.480 | 14.428 | 76.766 | 3.407 | 26.324 | 478.854 | 517.148 |
Total Income - EUR | 90.045 | 160.145 | 148.680 | 48.544 | 14.816 | 82.605 | 5.776 | 37.631 | 488.323 | 657.948 |
Total Expenses - EUR | 126.219 | 181.360 | 150.430 | 61.461 | 17.691 | 81.036 | 27.799 | 60.330 | 483.236 | 558.697 |
Gross Profit/Loss - EUR | -36.175 | -21.215 | -1.750 | -12.917 | -2.874 | 1.569 | -22.023 | -22.699 | 5.087 | 99.251 |
Net Profit/Loss - EUR | -36.175 | -21.215 | -1.750 | -13.423 | -3.020 | 801 | -22.057 | -22.963 | 291 | 99.251 |
Employees | 6 | 6 | 3 | 3 | 2 | 1 | 2 | 2 | 3 | 3 |
Check the financial reports for the company - Velimed Srl
2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Fixed Assets | 40.248 | 33.583 | 25.683 | 18.085 | 17.753 | 17.409 | 17.445 | 16.523 | 15.925 | 15.877 |
Current Assets | 5.259 | 506 | 898 | 8.393 | 6.383 | 15.559 | 12.642 | 18.417 | 26.298 | 40.610 |
Inventories | 1.130 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Receivables | 3.387 | 173 | 40 | 1.893 | 2.633 | 4.604 | 4.552 | 100 | 22.734 | 12.405 |
Cash | 741 | 333 | 857 | 6.500 | 3.749 | 10.955 | 8.090 | 18.317 | 3.564 | 28.206 |
Shareholders Funds | -43.136 | -64.711 | -65.801 | -78.110 | -74.754 | -72.506 | -93.188 | -114.084 | -114.147 | -14.550 |
Social Capital | 446 | 450 | 445 | 438 | 5.372 | 5.268 | 5.168 | 5.054 | 5.069 | 5.054 |
Debts | 65.731 | 77.332 | 92.381 | 104.360 | 98.890 | 102.251 | 125.075 | 134.984 | 142.487 | 21.061 |
Income in Advance | 22.911 | 21.468 | 0 | 7.117 | 0 | 5.103 | 1.840 | 22.958 | 35.680 | 62.642 |
Exchange rate - RON | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 | 4.4821 |
Main CAEN | "7912 - 7912" | |||||||||
CAEN Financial Year |
7912
|
Subscriptions Financial Reports
You can check the financial situation of the companies in relation to the industry of which it is a part, credit limits and the risk of insolvency and suspension of accounts.
Comments - Velimed Srl